Aevi Genomic Medicine   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Wayne PA United States (2000)
Status: Acquired by Cerecor Inc (2019)

Organization Overview

First Clinical Trial
2008
NCT00542568
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Aevi Genomic Medicine | Aevi Genomic Medicine, LLC, a Cerecor company | Medgenics Medical Israel Ltd.

Active Ingredients

Drugs in Phase 3 Trials (1)

fasoracetam (4 trials)

Drugs in Phase 2 Trials (5)

aevi-001 (2 trials)

autologous skin graft (1 trial)

cerc-002 (1 trial)

epoetin (Epogen) (1 trial)

mdgn201 (3 trials)

Drugs in Phase 1 Trials (2)

aevi-007 (1 trial)

mdgn-002 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 2)

Anemia (Phase 2)

Arachnodactyly (Phase 1)

Attention Deficit Disorder with Hyperactivity (Phase 3)

Craniosynostoses (Phase 1)

Crohn Disease (Phase 1)

DiGeorge Syndrome (Phase 1)

Genetic Diseases, Inborn (Phase 3)

Hyperkinesis (Phase 2)

Kidney Diseases (Phase 2)

Kidney Failure, Chronic (Phase 2)

Lung Injury (Phase 2)

Marfan Syndrome (Phase 1)

Multiple Myeloma (Phase 1)

Neoplasms, Plasma Cell (Phase 1)

Pneumonia (Phase 2)

Renal Insufficiency, Chronic (Phase 2)

Respiratory Distress Syndrome (Phase 2)

Syndrome (Phase 1)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial APIs: 8